Role of intermediate filaments in migration, invasion and metastasis

Cancer and Metastasis Reviews

Volumn 15, Issue 4, 1996, Pages 507-525

  Hendrix, Mary J C ^a,b   Seftor, Elisabeth A ^a,b   Chu, Yi Wen ^c   Trevor, Katrina T ^d   Seftor, Richard E B ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d ST LUKE S MEDICAL CENTER   (United States)

Author keywords

cancer; intermediate filaments; invasion; keratins; metastasis; vimentin

Indexed keywords

CYTOKERATIN; VIMENTIN;

BREAST CARCINOMA; CELL INVASION; CELL MIGRATION; HUMAN; HUMAN TISSUE; INTERMEDIATE FILAMENT; MELANOMA; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; CELL MOVEMENT; HUMANS; INTERMEDIATE FILAMENT PROTEINS; INTERMEDIATE FILAMENTS; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS;

EID: 0030474514     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00054016     Document Type: Review

References (105)

1. Rigel D, Kopf AW, Friedman RJ: The rate of malignant melanoma in the United States: Are we making an impact? J Am Acad Dermatol 17: 1050-1053, 1981
2. Raymond WA, Leong AS-Y: Vimentin - A new prognostic parameter in breast carcinoma? J Pathol 158: 107-114, 1989
3. Akslen LA, Hove LM, Harveit F: Metastatic distribution in malignant melanoma: A 30-year autopsy study. Invasion Metas 7: 253-263, 1987
4. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64: 327-336, 1991
5. Kohn EC, Liotta LA: Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 55: 1856-1862, 1995
6. Huszar M, Halkin H, Herczeg E, Bubis J, Geiger B: Use of antibodies to intermediate filaments in the diagnosis of metastatic melanoma. Human Pathol 14: 1006-1008, 1983
7. Osborn M, Weber K, Biology of disease: Tumor diagnosis by intermediate filament typing - A new tool for surgical pathology. Lab Invest 48: 372-394, 1983
8. Steinert PM, Leim RK: Intermediate filament dynamics. Cell 60: 521-523, 1990
9. Klymkowsky MW, Bachant JB, Domingo A: Functions of intermediate filaments. Cell Motility Cytoskel 14: 309-331, 1989
10. Skalli O, Goldman RD: Recent insights into the assembly, dynamics, and function of intermediate filament networks. Cell Motility Cytoskel 19: 67-79, 1991
11. Fuchs E, Weber K: Intermediate filaments: Structure, dynamics, function and disease. Annu Rev Biochem 63: 345-382, 1994
12. Osborn M, Weber K: Intermediate filaments: Cell-type-specific markers in differentiation and pathology. Cell 31: 303-306, 1982
13. Franke WW, Schmid E, Moll R: The intermediate filament cytoskeleton in tissues and in cultured cells: Differentiation specificity of expression of cell architectural elements. In: Harris CC, Autrup JN (eds) Human carcinogenesis, New York: Academic Press, 1983, pp 3-34
14. Hendrix MJC, Seftor EA, Chu Y-W, Seftor REB, Nagle RB, McDaniel KM, Leong SPL, Yohem KH, Leibovitz A, Meyskens FL, Conoway DH, Welch DR, Liotta LA, Stetler-Stevenson WG: Coexpression of vimentin and keratins by human melanoma tumor cells: Correlation with invasive and metastatic potential. J Natl Cancer Inst 84: 165-174, 1992
15. Miettinen M, Franssila K: Immunohistochemical spectrum of malignant melanoma: The common presence of keratins. Lab Invest 61: 623-628, 1989
16. Zarbo RJ, Gown AM, Nagle RB: Anomalous cytokeratin expression in malignant melanoma: One- and two-dimensional Western blot analysis and immunohistochemical survey of 100 melanomas. Mod Pathol 3: 494-501, 1990
17. Thompson EW, Soonmyoung P, Brunner N, Sommers CL, Sugmaler G, Clarke R, Shima TB, Torri J, Donahue S, Lippmann ME, Martin GR, Dickson RB: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544, 1992
18. Cattoretti G, Andreola S, Clemente C, D'Amato L, Rilke F: Vimentin and p53 expression on EGFr-positive, estrogen receptor-negative breast carcinomas. Br J Cancer 57: 353-357, 1988
19. Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW, Byers SW, Gelmann EP: Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 52: 5190-5197, 1992
20. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP: Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 31: 325-335, 1994
21. Bianchi E, Cohen RL, Dai A, Thor AD, Shuman MA, Smith HA: Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60: 597-603, 1995
22. Ben-Ze'ev A, Zoller M, Raz A: Differential expression of intermediate filament proteins in metastatic and nonmetastatic variants of the Bsp73 tumor. Cancer Res 46: 785-790, 1986
23. Ramaekers FCS, Haag D, Kant A, Moesker O, Jap PHK, Vooljs GP: Coexpression of keratin- and vimentin-type intermediate filaments in human metastatic carcinoma cells. Proc Natl Acad Sci USA 80: 2618-2622, 1983
24. Gunther A, Kinjo M, Winter H, Sonka J, Volm D: Differential expression of intermediate-filament proteins in murine sarcoma 180 ascites of solid tumor. Cancer Res 44: 2590-2594, 1984
25. Kinjo M, Winter H, Schweizer J: Differential expression of intermediate filament proteins in two rat ascites hepatoma lines of common origin. Carcinogenesis 5: 1249-1255, 1984
26. Stewart M: Intermediate filaments: Structure, assembly and molecular interactions. Current Opin Cell Biol 12: 91-100, 1994
27. Florenes VA, Holm R, Myklebost O, Lendahl U, Fodstad O: Expression of the neuroectodermal intermediate filament nestin in human melanomas. Cancer Res 54: 354-356, 1994
28. Fuchs E, Marchuk D: Type I and type II keratins have evolved from lower eukaryotes to form the epidermal intermediate filaments in mammalian skin. Proc Natl Acad Sci USA 80: 5857-5861, 1983
29. Steinert PM: The two-chain coiled-coil molecule of native epidermal keratin intermediate filaments is a type I-type II heterodimer. J Biol Chem 265: 8766-8774, 1990
30. Fuchs E: Epidermal differentiation: The bare essentials. J Cell Biol 111: 2807-2814, 1990
31. Oshima RG, Howe WE, Klier FG, Adamson ED, Shevinsky LH: Intermediate filament protein synthesis in preimplantation murine embryos. Dev Biol 99: 447-455, 1983
32. Duprey P, Morello D, Vasseur M, Babinet C, Condamine H, Brulet P, Jacob F: Expression of the cytokeratin endo A gene during early mouse embryogenesis. Proc Natl Acad Sci USA 82: 8535-8539, 1985
33. Lane EB, Hogan BLM, Kurkinen M, Garrels JI: Co-expression of vimentin and cytokeratins in parietal endoderm cells of early mouse embryo. Nature 303: 701-703, 1983
34. Trejdosiewicz LK, Southgate J, Kemshead JT: Phenotypic analysis of cultured melanoma cells: Expression of cytokeratin-type intermediate filaments by the M5 human melanoma cell line. Exp Cell Res 164: 388-398, 1986
35. Rosen EM, Nigam SK, Goldberg ID: Scatter factor and the c-met receptor: A paradigm for mesenchymal/epithelial interaction. J Cell Biol 127: 1783-1787, 1994
36. Tyner AL, Fuchs E: Evidence for posttranslational regulation of the keratins expressed during hyperproliferation and malignant transformation in human epidermis. J Cell Biol 103: 1945-1955, 1986
37. Knapp AC, Franke WW: Spontaneous losses of control of cytokeratin gene expression in transformed, non-epithelial human cells occurring at different levels of regulation. Cell 59: 67-79, 1989
38. Oshima RG, Abrams L, Kulesh D: Activation of an intron enhancer within the keratin 18 gene by expression of c-fos and c-jun in undifferentiated F9 embryonal carcinoma cells. Genes Dev 4: 835-848, 1990
39. Oshima RG: Intermediate filament molecular biology. Curr Opin Cell Biol 4: 110-116, 1992
40. Fuchs E: Intermediate filaments and disease: Mutations that cripple cell strength. J Cell Biol 125: 511-516, 1994
41. Hay ED: Theory for epithelial-mesenchymal transformation based on the 'fixed cortex' cell motility model. Cell Motil Cytoskeleton 14: 455-457, 1989
42. McDonald JA: Matrix regulation of cell shape and gene expression. Curr Opin Cell Biol 1: 995-999, 1989
43. Steuli CH, Bissell MJ: Mammary epithelial cells, extracellular matrix and gene expression. Cancer Treat Res 53: 365-381, 1991
44. Juliano RL, Haskill S: Signal transduction from the extracellular matrix. J Cell Biol 120: 577-585, 1993
45. Ginsberg MH, Du X, Plow EF: Inside-out integrin signaling. Curr Opin Cell Biol 4: 766-771, 1992
46. Ingber D: Integrins as mechanochemical transducers. Curr Opin Cell Biol 3: 841-848, 1991
47. Akiyama SK, Nagata K, Yamada KM: Cell surface receptors for extracellular matrix components. Biochem Biophys Acta 103: 91-109, 1990
48. Albelda SM, Buck CA: Integrins and other cell adhesion molecules. FASEB J 4: 2868-2880, 1990
49. Ruoslahti E: Integrins. J Clin Invest 87: 1-5, 1991
50. Matrisian M: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6: 121-125, 1990
51. Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Phys Rev 73: 161-195, 1993
52. Sloane BF: Cathepsin B and cystatins: Evidence for a role in cancer progression. Semin Cancer Biol 1: 137-152, 1990
53. Bernhard EJ, Gruber SB, Muschel RJ: Direct evidence linking the expression of MMP-9 to the transformed phenotype in transformed rat cells. Proc Natl Acad Sci USA, 1994
54. Liotta LA, Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Semin Cancer Biol 1: 99-106, 1990
55. Werb Z, Tremble PM, Behrendtsen O, Crowlev E, Damsky CH: Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol 109: 877-889, 1989
56. 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 89: 157-1561, 1992
57. 1 integrins during human melanoma cell invasion. Cancer Res 53: 3411-3415, 1993
58. Quaranta V, Jones JCR: The internal affairs of an integrin. Trends Cell Biol 1: 2-4, 1991
59. 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol 113: 919-929, 1991
60. Tawil N, Wilson P, Carbonetto S: Integrins in point contacts mediate spreading. J Cell Biol 120: 261-271, 1993
61. Miyamoto S, Teramoto H, Coso OA, Gutkind JS, Burbelo PD, Akiyama SK, Yamada KM: Integrin function: Molecular hierarchies of cytoskeletal and signaling molecules. J Cell Biol 131: 791-805, 1995
62. Green KJ, Goldman RD: Evidence for an interaction between the cell surface and intermediate filaments in cultured fibroblasts. Cell Motil Cyto 6: 389-405, 1986
63. 1 integrin subunit in vitro. J Cell Biol 111: 721-729, 1990
64. Chu Y-W, Seftor EA, Romer LH, Hendrix MJC: Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility. Am J Pathol 148: 63-69, 1996
65. Hynes RO: Integrins: Versatility, modulation and signaling in cell adhesion. Cell 69: 11-25, 1992
66. Ruoslahti E: Control of cell motility and tumor invasion by extracellular matrix interactions, Br J Cancer 66: 239-242, 1992
67. 1 integrins. Proc Natl Acad Sci USA 88: 8392-8396, 1991
68. Romer LH, McLean N, Turner CE, Burridge K: Tyrosine kinase activity, cytoskeletal organization and motility in human vascular endothelial cells. Mol Biol Cell 5: 349-361, 1994
69. Nuckolls GH, Romer LH, Burridge K.: Microinjection of antibodies against talin inhibits the spreading and migration of fibroblasts. J Cell Sci 102: 753-762, 1992
70. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L: Induction of cell migration by pro-urokinase binding to its receptor. Possible mechanism tor signal transduction in human epithelial cells. J Cell Biol 126: 259-270, 1994
71. Chou C-F, Omary MB: Mitotic-arrest associated enhancement of O-linked glycosylation and phosphorylation of human keratins 8 and 18. J Biol Chem 268: 4456-4472, 1993
72. Liao J, Lowthert LA, Ku N-O, Fernandex R, Omary MB: Dynamics of human keratin 18 phosphorylation: Polarized distribution of phosphorylated keratins in simple epithelial tissues. J Cell Biol 131: 1291-1301, 1995
73. 125 accompanies cell adhesion to extracellular matrix: A role in cytoskeletal assembly. J Cell Biol 119: 893-903, 1992
74. Kornberg LJ, Earp HS, Parsons JT, Schaller M, Juliano RL: Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. J Biol Chem 267: 23439-23442, 1992
75. Weiner TM, Liu ET, Craven RJ, Cance WG: Expression of focal adhesion kinase gene and invasive cancer. Lancer 342: 1024-1025, 1993
76. EAK) in invasive human tumors. Cancer Res 55: 2752-2755, 1995
77. Chu YW, Duffy JJ, Seftor REB, Hendrix MJC: Disruption of normal cytokeratin formation by the transfection of a detected CK18 cDNA into a highly metastatic melanoma cell line decreases the invasive potential. J Clin Biotch 3: 27-33, 1991
78. Hendrix MJC, Seftor HA, Seftor REB, Fidler IJ: A simple quantitative assay for studying the invasive potential of high and low metastatic variants. Cancer Lett 38: 137-147, 1987
79. Boring CC, Squires TS, Tong T: Cancer statistics. Cancer J Clin 20: 7-26, 1993
80. Domagala W, Lasota J, Bartowiak J, Weber K, Osborn M: Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 136: 219-227, 1990
81. Domagala W, Leszek W, Lasota J, Weber K, Osborn M: Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas. Am J Pathol 137: 1059-1064, 1990
82. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR, Dickson RB: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544, 1992
83. Sommers CL, Walker-Jones D, Heckford SE, Worland P, Valverius E, Clark R, Stampfer M, Gelmann EP: Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines in oncogene-transformed mammary epithelial cells. Cancer Res 49: 4258-4263, 1989
84. McLean WHI, Lane EB: Intermediate filaments in disease: Current Opin Cell Biol 7: 118-125, 1995
85. Klymkowsky MW: Intermediate filaments: new proteins, some answers, more questions: Current Opin Cell Biol 7: 46-54, 1995
86. McCarthy JB, Palm SL, Furcht LT: Migration by haptotaxis of a Schwann cell tumor cell line to the basement membrane glycoprotein laminin. J Cell Biol 97: 772-777, 1983
87. Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461-463, 1977
88. Stetler-Stevenson WG, Aznavoorian S, Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9: 541-573, 1993
89. Chu Y-W, Runyan RB, Oshima RG, Hendrix MJC: Expression of complete keratin filaments in mouse L cells augments cell migration and invasion. Proc Natl Acad Sci USA 90: 4261-4265, 1993
90. Sarria AJ, Nordeen SK, Evans RM: Regulated expression of vimentin cDNA in cells in the presence and absence of a preexisting vimentin filament network. J Cell Biol 111: 553-565, 1990
91. Trevor KT: Disruption of keratin filaments in embryonic epithelial cell types. New Biol 2: 1004-1014, 1990
92. Gunning P, Leavitt J, Muscat G, Ng S-Y, Kedes L: A human beta-actin expression vector system directs high level accumulation of antisense transcripts. Proc Natl Acad Sci USA 84: 4831-4835, 1987
93. Gorman CM, Merlino GT, Willingham MC, Pastan I, Howard BH: The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci USA 79: 6777-6781, 1982
94. Andreoli JM, Trevor KT: Structural and biological consequences of increased vimentin expression in simple epithelial cell types. Cell Motil Cytoskel 32: 10-25, 1995
95. Bauman PA, Dalton WS, Anderson JM, Cress AE: Expression of cytokeratin cofers multiple drug resistance. Proc Natl Acad Sci USA 91: 5311-5314, 1994
96. Potts JD, Dagle JM, Walder JA, Weeks DL, Runyan RB: Epithelial-mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligodeoxynucleotide to transforming growth factor β3. Proc Natl Acad Sci USA 88: 1516-1520, 1991
97. Shea TB, Beermann ML, Fischer I: Transient requirement for vimentin in neuritogenesis: intracellular delivery of anti-vimentin antibodies and antisense oligonucleotides inhibit neurite initiation but not elongation of existing neurites in neuroblastoma. J Neurosci Res 36: 66-76, 1993
98. Maiorana A, Cesinaro AM, Fano RA, Collina G: Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases. Clin Exp Metas 13: 43-48, 1995
99. Lichtner RB, Julian JA, North SM, Glasser SR, Nicolson GL: Coexpression of cytokeratins characteristic for myoepithelial and luminal cell lineages m rat 1376NF mammary adenocarcinoma tumors and their spontaneous metastases. Cancer Res 51: 5943-5950, 1991
100. Stover DM, Carey I, Garzon RJ, Zehner ZE: A negative regulatory factor is missing in a human metastatic breast cancer cell line. Cancer Res 54: 3092-3095, 1994
101. Griffith CM, Hay ED: Epithelial-mesenchymal transformation during palatal fusion: carboxyfluorescein traces cells at light and electron microscopic levels. Development 116: 1087-1099, 1992
102. Miyamoto S, Teramoto H, Coso OA, Gutkind JS, Burbelo PD, Akiyama SK, Yamada KM: Integrin function: Molecular hierarchies of cytoskeletal and signaling molecules. J Cell Biol 131: 791-805, 1995
103. Kobota S, Tashiro K, Yamada Y: Signaling site of laminin with mitogenic activity. J Biol Chem 257: 4285-4288, 1992
104. 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci USA 92: 7411-7415, 1995
105. Lynch RG: Differentiation and cancer. Proc Natl Acad USA 92: 647-648, 1995